Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 12, 2025
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
Read more at globenewswire.comNASDAQ:DRTSW (11/25/2025, 8:00:01 PM)
0.34
+0.02 (+6.55%)
NASDAQ:DRTS (11/26/2025, 1:59:53 PM)
3.72
-0.18 (-4.62%)
Find more stocks in the Stock Screener
